Anavex Life Sciences Corp (NASDAQ:AVXL) has announced that the United States Patent and trademark Officer (USPTO) has granted it a Notice of Allowance for its patent application number 16/717,921. The patent expands coverage for ANAVEX®2-73 (blarcamesine) treatment methods and associated sigma-1 receptor agonist drugs for rare neurodevelopmental disorders treatment. Some of the disorders covered include autism spectrum disorder, Rett syndrome, cerebral palsy, multiple sclerosis, and Angelman syndrome among other indications.
Anavex expanding patent claims
According to data, the activation of the sigma-1 receptor is vital in neural cell hemostasis restoration and promotion of neuroplasticity. The latest YS patent will remain effective until 2037 excluding any patent extensions. The patent plus the US patent No. 10,507196 issued to Anavex at the beginning of this year will expand the patent claim coverage for the use of sigma-1 receptor agnostic in transdermal, oral, and parenteral compositions including in adult and pediatric patients.
Christopher U. Missling, Anavex’s CEO, said that patent allowance is a significant milestone in the protection of ANAVEX®2-73’s commercial potential as well as other lead products of the company. Missling added that the patent alongside recent allowances shows the company’s strong commitment to protecting commercial opportunity and innovation of Anavex’s whole product portfolio.
Anavex evaluating ANV+AVEX®2-73 in Rett Syndrome
The company is evaluating ANAVAX®2-73 for Rett Syndrome in two ongoing placebo-controlled studies and one completed trial. Anavex treated adult Rett syndrome in the completed phase 2 study in the US with low ANAVEX®2-73 oral liquid formulation dose. Subsequent AVATAR Phase 2 study in adult Rett syndrome and EXCELLENCE phase 2/3 study in pediatric Rett syndrome are evaluating high ANAVEX®2-73 oral liquid formulation dose. The FDA had previously granted ANAVEX®2-73 Rare Paediatric Disease, Fast Track and Orphan Drug designations for Rett syndrome treatment.
ANAVEX®2-73 is the company’s lead product candidate that recently completed Phase 2a clinical studies in Alzheimer’s diseases and a second phase proof-of-concept trial in Parkinson’s disease dementia. The orally available formulation restores cellular homeostasis through targeting of muscarinic and sigma-1 receptors. The drug has demonstrated the potential to reverse Alzheimer’s disease.
